Stockreport

X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome

X4 Pharmaceuticals, Inc.  (XFOR) 
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am Check Earnings Report
PDF CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeuti [Read more]